Baxter International Inc
NYSE:BAX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.4108
36.57
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
BAX
stock under the Base Case scenario is
43.95
USD.
Compared to the current market price of 19.33 USD,
Baxter International Inc
is
Undervalued by 56%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Baxter International Inc.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Baxter’s recent supply chain disruptions, combined with ongoing product recalls in its infusion pump portfolio, threaten to erode the company’s reputation for quality and could lead to higher costs and reduced revenue growth in the near term.
The company’s strategic decisions, including the planned spin-off of its renal care and acute therapies segments, risk diverting management’s focus and disrupting operational efficiency, potentially undermining expected synergistic benefits and near-term profitability.
Intensifying competition from established players in dialysis (Fresenius Medical Care) and infusion systems (B. Braun) could pressure Baxter to invest heavily in R&D or pricing strategies, contracting margins and reducing returns on capital.
Baxter’s diversified portfolio—spanning infusion systems, renal care, and advanced surgery products—positions the firm to capture steady growth, as healthcare providers increasingly seek proven, integrated solutions from a single partner.
The planned separation of certain business lines, such as Baxter’s biopharma solutions business, may unlock shareholder value through more targeted strategic direction and improved capital allocation, amplifying both segments’ profit potential.
With ongoing investments in digital health tools and next-generation infusion technologies, Baxter stands to capitalize on emerging trends in precision medicine and telehealth, enhancing its competitive edge and supporting robust long-term growth.
Revenue & Expenses Breakdown
Baxter International Inc
Balance Sheet Decomposition
Baxter International Inc
| Current Assets | 6.9B |
| Cash & Short-Term Investments | 1.7B |
| Receivables | 1.8B |
| Other Current Assets | 3.4B |
| Non-Current Assets | 14.1B |
| PP&E | 3.1B |
| Intangibles | 10.2B |
| Other Non-Current Assets | 847m |
| Current Liabilities | 3.8B |
| Accounts Payable | 953m |
| Accrued Liabilities | 1.9B |
| Short-Term Debt | 4m |
| Other Current Liabilities | 875m |
| Non-Current Liabilities | 10.1B |
| Long-Term Debt | 8.7B |
| Other Non-Current Liabilities | 1.3B |
Free Cash Flow Analysis
Baxter International Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Baxter International Inc
|
Revenue
|
11B
USD
|
|
Cost of Revenue
|
-7.2B
USD
|
|
Gross Profit
|
3.9B
USD
|
|
Operating Expenses
|
-3.2B
USD
|
|
Operating Income
|
702m
USD
|
|
Other Expenses
|
-1B
USD
|
|
Net Income
|
-341m
USD
|
BAX Profitability Score
Profitability Due Diligence
Baxter International Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Baxter International Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
BAX Solvency Score
Solvency Due Diligence
Baxter International Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Baxter International Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BAX Price Targets Summary
Baxter International Inc
According to Wall Street analysts, the average 1-year price target for
BAX
is 24.55 USD
with a low forecast of 15.15 USD and a high forecast of 50.41 USD.
Dividends
Current shareholder yield for
BAX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BAX
stock under the Base Case scenario is
43.95
USD.
Compared to the current market price of 19.33 USD,
Baxter International Inc
is
Undervalued by 56%.